Starling Oncology, Inc.: updates and filings

STLNNASDAQHealthcare · Services-Offices & Clinics of Doctors of Medicine

Price

$3.29

November 19, 2026Market cap $326M

What Ploutos Investor adds for Starling Oncology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 52% since Nov 5, 2026, when the 10-Q these figures come from was filed ($6.70 then, $3.20 on Nov 18, 2026). The figures date from before that move.10-Q

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 78 daysAround Feb 5, 2027 · for Q4 2026

last Nov 5, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 12, 2026 latest annualNov 6, 2026 latest quarterly
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • Nov 12, 2026Regulation FD disclosure (amendment)
    Form8-K/A
  • Nov 12, 2026Regulation FD disclosure
    Form8-K
  • Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Results of operations
    Form8-K
  • Sep 2, 2026Officer or director change
    Form8-K
  • Aug 21, 2026Material agreement entered, new material financial obligation
    Form8-K
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations
    Form8-K
  • Aug 3, 2026Amended articles or bylaws, Regulation FD disclosure
    Form8-K
  • Jul 7, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Jun 18, 2026Shareholder vote
    Form8-K
  • May 22, 2026Material cybersecurity incident
    Form8-K
  • May 15, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 7, 2026Results of operations
    Form8-K
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 30, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 30, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Mar 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 13, 2026Regulation FD disclosure
    Form8-K
  • Mar 12, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 12, 2026Results of operations
    Form8-K
  • Feb 23, 2026Officer or director change, Regulation FD disclosure
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 14, 2020.

The full analysis

What do Starling Oncology's filings show?

The filings are where every one of Starling Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.